Defining the Starting Dose

[1]  J. Verweij,et al.  Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Groshen,et al.  Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. , 2002, Journal of the National Cancer Institute.

[3]  Brigitte Tranchand,et al.  Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials. , 2002, British journal of clinical pharmacology.

[4]  H. Gurney,et al.  How to calculate the dose of chemotherapy , 2002, British Journal of Cancer.

[5]  H. Groen,et al.  Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene , 2002, British Journal of Cancer.

[6]  Hideyuki Saito,et al.  Gene expression levels and immunolocalization of organic ion transporters in the human kidney. , 2002, Journal of the American Society of Nephrology : JASN.

[7]  C. Klaassen,et al.  Induction of rat organic anion transporting polypeptide 2 by pregnenolone-16alpha-carbonitrile is via interaction with pregnane X receptor. , 2002, Molecular pharmacology.

[8]  Paul T Tarr,et al.  Regulation of Multidrug Resistance-associated Protein 2 (ABCC2) by the Nuclear Receptors Pregnane X Receptor, Farnesoid X-activated Receptor, and Constitutive Androstane Receptor* , 2002, The Journal of Biological Chemistry.

[9]  D. V. Von Hoff,et al.  Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Hudson,et al.  The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. , 2001, Pharmacogenetics.

[11]  J. Verweij,et al.  Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Kigawa,et al.  Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. , 2001, The Journal of pharmacology and experimental therapeutics.

[13]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[14]  L Landmann,et al.  Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. , 2001, Gastroenterology.

[15]  S. Poole,et al.  Poor correlation between body surface area and glomerular filtration rate , 2000, Cancer Chemotherapy and Pharmacology.

[16]  A. Cranendonk,et al.  Clinical pharmacokinetics of phenobarbital in neonates. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  S. Chan,et al.  Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. , 2000, British journal of clinical pharmacology.

[18]  J. Bergh,et al.  Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial , 2000, The Lancet.

[19]  Sudhakar M. Pai,et al.  Population Pharmacokinetics of Temozolomide in Cancer Patients , 2000, Pharmaceutical Research.

[20]  P. Beale,et al.  Optimizing the erythromycin breath test for use in cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  D. Xuan,et al.  Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen. , 2000, International journal of antimicrobial agents.

[22]  J. Verweij,et al.  Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  J. Beijnen,et al.  The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[24]  G. Weiss,et al.  Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Robert,et al.  Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Sockrider,et al.  Pharmacokinetics of Ibuprofen in Patients with Cystic Fibrosis , 1999, Pharmacotherapy.

[27]  Kyoichi Ohashi,et al.  Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer , 1998, Annals of Internal Medicine.

[28]  P. Angus,et al.  Relationships among liver and kidney volumes, lean body mass and drug clearance. , 1998, British journal of clinical pharmacology.

[29]  N. Dobbs,et al.  What is the effect of adjusting epirubicin doses for body surface area? , 1998, British Journal of Cancer.

[30]  M. Czuczman,et al.  Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  V. Gebski,et al.  Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Ratain.  Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  T. Yasuzawa,et al.  Identification of novel metabolites of vinorelbine in rat. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[34]  L. Nguyen,et al.  Population pharmacokinetics of total and unbound etoposide , 1997, Cancer Chemotherapy and Pharmacology.

[35]  B. Ring,et al.  The human drug metabolizing cytochromes P450 , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[36]  H. Gurney,et al.  Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Lewis B. Sheiner,et al.  A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[38]  H. Rosing,et al.  Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  O. Dassonville,et al.  [Population study of dihydropyrimidine dehydrogenase in cancer patients]. , 1994, Bulletin du cancer.

[40]  D. Morgan,et al.  Lean Body Mass as a Predictor of Drug Dosage , 1994, Clinical pharmacokinetics.

[41]  P. Workman,et al.  Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? , 1993, Cancer Chemotherapy and Pharmacology.

[42]  G Cheymol,et al.  Clinical Pharmacokinetics of Drugs in Obesity , 1993, Clinical pharmacokinetics.

[43]  A. van der Gaast,et al.  What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 x 100 mg, 2 x 50 mg, and 4 x 25 mg of oral etoposide daily for 21 days. , 1992, Seminars in oncology.

[44]  R. Motzer,et al.  Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience. , 1992, Seminars in oncology.

[45]  C. Hunt,et al.  Effect of age and gender on the activity of human hepatic CYP3A. , 1992, Biochemical pharmacology.

[46]  J. Rodman,et al.  The pharmacokinetics of high‐dose carboplatin in pediatric patients with cancer , 1992, Clinical pharmacology and therapeutics.

[47]  C. Stewart,et al.  Disposition of high‐dose methotrexate in an obese cancer patient , 1991, Cancer.

[48]  M. Green,et al.  Pharmacokinetics and toxicity of two schedules of high dose epirubicin. , 1990, Cancer research.

[49]  L. Grochow,et al.  Is dose normalization to weight or body surface area useful in adults? , 1990, Journal of the National Cancer Institute.

[50]  E Wiltshaw,et al.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  D. DuBois,et al.  A formula to estimate the approximate surface area if height and weight be known , 1989 .

[52]  D. Rushing,et al.  Doxorubicin clearance in the obese. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  M Slavik,et al.  Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. , 1975, Cancer research.

[54]  E J Freireich,et al.  Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. , 1966, Cancer chemotherapy reports.

[55]  D. Pinkel.  The use of body surface area as a criterion of drug dosage in cancer chemotherapy. , 1958, Cancer research.

[56]  Homer W. Smith.  The Kidney: Structure and Function in Health and Disease , 1952 .

[57]  J. Crawford,et al.  Simplification of drug dosage calculation by application of the surface area principle. , 1950, Pediatrics.

[58]  D. D. Bois,et al.  CLINICAL CALORIMETRY: TENTH PAPER A FORMULA TO ESTIMATE THE APPROXIMATE SURFACE AREA IF HEIGHT AND WEIGHT BE KNOWN , 1916 .

[59]  M. Millward,et al.  Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer , 2004, Cancer Chemotherapy and Pharmacology.

[60]  P. Wilkinson,et al.  Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution , 2004, Cancer Chemotherapy and Pharmacology.

[61]  J. Ingle,et al.  Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients , 2004, Cancer Chemotherapy and Pharmacology.

[62]  K. Itoh,et al.  Factors Affecting the Pharmacokinetics of CPT-11: The Body Mass Index, Age and Sex are Independent Predictors of Pharmacokinetic Parameters of CPT-11 , 2004, Investigational New Drugs.

[63]  E. Berry,et al.  Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism , 2004, European Journal of Clinical Pharmacology.

[64]  B. Goodwin,et al.  Regulation of hepatic drug metabolism: role of the nuclear receptors PXR and CAR. , 2002, Seminars in liver disease.

[65]  J. Verweij,et al.  Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  R. Schilsky,et al.  UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity , 2002, The Pharmacogenomics Journal.

[67]  M. Ratain,et al.  Pharmacogenetics , 2000, Clinical pharmacokinetics.

[68]  N. Mcintyre,et al.  Oxford Textbook of Clinical Hepatology , 1999 .

[69]  F. Appelbaum,et al.  The impact of obesity and disease on busulfan oral clearance in adults. , 1999, Blood.

[70]  L B Sheiner,et al.  Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  T. Goya,et al.  The influence of relative body weight on toxicity of combination chemotherapy with cisplatin and etoposide , 1998, Cancer Chemotherapy and Pharmacology.

[72]  G. Bonadonna,et al.  Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  Malcolm Rowland,et al.  Clinical pharmacokinetics : concepts and applications , 1989 .

[74]  M. Schnegg,et al.  Quantitative liver function in the elderly assessed by galactose elimination capacity, aminopyrine demethylation and caffeine clearance. , 1986, Journal of hepatology.